ReviewCurrent HIV/AIDS reports2015
Type I interferon: understanding its role in HIV pathogenesis and therapy.
Review in Current HIV/AIDS reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Transcriptional insights into the CD8Journal of translational medicine · 2020Pooled it
- Transcriptomic meta-analysis identifies gene expression characteristics in various samples of HIV-infected patients with nonprogressive disease.Journal of translational medicine · 2017Pooled it
- Persistent activation of monocytes/macrophages and cell senescence in SIV-infected macaques on ART.Frontiers in immunology · 2026Article
- Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART.bioRxiv : the preprint server for biology · 2025Article
- Early Transcriptomic Signatures of Immune Response Modulation Following Antiretroviral Therapy in HIV-Infected Patients.International journal of molecular sciences · 2025Article
- Liver biopsies obtained throughout SIV infection reveal evolving interferon stimulated protein expression within distinct monocyte/macrophage subsets.PLoS pathogens · 2025Article
- Establishment of a reverse genetics system for studying human immune functions in mice.Science advances · 2025Article
- Review
- HIV controllers: hope for a functional cure.Frontiers in immunology · 2025Review
- Integrated analysis of rectal mucosal microbiome and transcriptome reveals a distinct microenvironment among young MSM.JCI insight · 2024Article
- The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice.PLoS pathogens · 2024Article
- Unmasking the hidden impact of viruses on tuberculosis risk.Trends in immunology · 2024Review
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- IFNα Subtypes in HIV Infection and Immunity.Viruses · 2024Review
- Pro-inflammatory feedback loops define immune responses to pathogenic Lentivirus infection.Genome medicine · 2024Article
- Dectin-1 stimulation promotes a distinct inflammatory signature in the setting of HIV-infection and aging.Aging · 2023Article
- Immunomodulatory Role of Interferons in Viral and Bacterial Infections.International journal of molecular sciences · 2023Review
- Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?Current HIV/AIDS reports · 2023Review
- SARS-CoV-2, HIV, and HPV: Convergent evolution of selective regulation of cGAS-STING signaling.Journal of medical virology · 2023Review
- cART Restores Transient Responsiveness to IFN Type 1 in HIV-Infected Humanized Mice.Journal of virology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite over 30 years of research, the contribution of type I interferons (IFN-Is) to both the control of HIV replication and initiation of immunologic damage remains debated. In acute infection, IFN-Is, likely from plasmacytoid dendritic cells (pDCs), activate NK cells and upregulate restriction factors targeting virtually the entire HIV life cycle. In chronic infection, IFN-Is may also contribute to CD4 T cell loss and immune exhaustion. pDCs subsequently infiltrate lymphoid and mucosal tissues, and their circulating populations wane in chronic infection; IFN-I may be produced by other cells. Data from nonhuman primates indicate prompt IFN-I signaling is critical in acute infection. Whereas some studies showed IFN-I administration without combination antiretroviral therapy (cART) is beneficial, others suggest that stimulating or blocking IFN-I signaling in chronic ART-suppressed HIV infection has had positive results. Here, we describe the history of HIV and IFN-I, IFN-I's sources, IFN-I's effects on HIV control and host defense, and recent interventional studies in SIV and HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.